World Awaits Bankman-Fried Sentence, Drug Stock Pump-And-Dump, Penny Stock Fraud: Financial Crimes Weekly
"Thousands of ordinary people lost their savings," said prosecutors in the trial of Sam Bankman-Fried this week, urging the judge to enact the harshest possible punishment when the disgraced founder o
Oncology Pharma Inc. (OTCMKTS:ONPH) Sees Significant Increase in Short Interest
Oncology Pharma Inc. (OTCMKTS:ONPH – Get Rating) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 27,300 shares,
Oncology Pharma Inc. (OTCMKTS:ONPH) Short Interest Update
Oncology Pharma Inc. (OTCMKTS:ONPH – Get Rating) was the target of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 22,900 shares, a dr
Oncology Pharma Inc. (OTCMKTS:ONPH) Short Interest Up 28.8% in January
Oncology Pharma Inc. (OTCMKTS:ONPH – Get Rating) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 30,400 shares, a growth of 28.8%
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to execute its next phase with Connect2Trials, Inc. Originally, t
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
SAN FRANCISCO, CA / ACCESSWIRE / April 13, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma ("The Company") is pleased to announce that it has completed the initial feasibility phase of its
Oncology Pharma Reports on Progress with Ribera Solutions
SAN FRANCISCO, CA / ACCESSWIRE / March 2, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce progress with its investment with Ribera Solutions'
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the studies under the Co-Dev
Oncology Pharma Expands on Feasibility Studies and Data
SAN FRANCISCO, CA / ACCESSWIRE / February 17, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") wants to expand on a previously announced press release that included
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
SAN FRANCISCO, CA / ACCESSWIRE / February 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce that the co-development agreement and ongoing wo
Oncology Pharma's New Year Update
SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") update on its progress to kick off the new year.The Company has advance
Oncology Pharma Meeting Towards Future Developments
SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. ("The Company") conducted a meeting with the Board of Directors, executives, and Scienti
Oncology Pharma slips on year-end operational update
Oncology Pharma (OTCPK:ONPH -7.1%) is on the decline following a year-end update on its portfolio and operations. The drug developer, which is focused on pediatrics and orphan drugs, is currently wor
Oncology Pharma Year End Review and Outlook
SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") and its Chief Executive are pleased to give a year end update and provi
Oncology Pharma Research and Vision
SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is a pioneering oncology company dedicated to providing the financing
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceut
Facebook Inc postponed the return of American employees to the office until 2022.
Facebook Inc postponed plans to return to the office because of the renewed surge in Covid-19 cases and informed US employees on Thursday that they did not need to return to the office until January 2022. "in view of the recent health data showing an increase in Delta infection, our US team does not have to return to the office until January 2022," Facebook Inc spokesman Tracy Clayton said in a statement. "We expect the same to be true in some countries outside the United States. We will continue to monitor the situation and work with experts to ensure that our return to the office is a priority.
Goldman Sachs Group: the bullish power of the oil market shifts from demand to supply
Download Sina Finance APP for more information and Big V views original title: Goldman Sachs Group: oil market bullish power from demand to supply in recent days, Goldman Sachs Group said that the net impact of the Delta variant virus on global oil demand forecast is still moderate, and global oil demand will remain at 97.8 million b / d in the next two months, slightly lower than the actual demand of 98.4 million b / d in July. It should be noted that in July, when OPEC + reached an agreement to gradually increase production, Goldman Sachs Group remained optimistic about the future of crude oil. In the latest report, Goldman Sachs Group continued to sing long: "the latest supply data confirm our view, that is,
No Data